Kither Biotech develops signal transduction modulators, specifically the cAMP modulating peptide KIT2014 and the PI3K inhibitor KITCL27, for the treatment of rare respiratory diseases such as cystic fibrosis and idiopathic pulmonary fibrosis. These therapies target critical pathways involved in lung function, addressing the persistent lung infections and breathing difficulties associated with these conditions.
Funding
$20.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
2CVFounders
Product
Problem
Cystic fibrosis and idiopathic pulmonary fibrosis are rare respiratory diseases characterized by persistent lung infections and breathing difficulties, resulting in a high unmet medical need. Current treatments often fail to adequately address the underlying signaling pathways that contribute to disease progression.
Solution
Kither Biotech develops signal transduction modulators to treat rare respiratory diseases. Their lead compound, KIT2014, is a cAMP modulating peptide for cystic fibrosis, designed to disrupt the interaction of PI3Kgamma with protein kinase A (PKA), leading to the inhibition of phosphodiesterases (PDE3/4) and enhanced cAMP responses within the cell. The company is also developing KITCL27, a small molecule PI3K inhibitor, as a prodrug for the treatment of Idiopathic Pulmonary Fibrosis, designed to block the enzymatic function of all members of the PI3K family.
Target Audience
The primary target audience includes patients suffering from cystic fibrosis and idiopathic pulmonary fibrosis, as well as healthcare providers specializing in the treatment of rare respiratory diseases.
Features
- KIT2014: Cell-permeable cAMP modulating peptide that disrupts PI3Kgamma-PKA interaction.
- KIT2014: Designed to inhibit PDE3/4, enhancing cAMP responses.
- KIT2014: Designated as an orphan drug by the European Medicines Agency for cystic fibrosis treatment.
- KITCL27: Small molecule inhibitor designed to block the enzymatic function of all PI3K family members.
- KITCL27: Being developed as a prodrug for Idiopathic Pulmonary Fibrosis.
- Therapies target the PI3K signaling pathway.